News

Top 10 ALS stories of 2023

Throughout 2023, ALS News Today brought you daily coverage of the latest clinical research and scientific breakthroughs related to amyotrophic lateral sclerosis (ALS). Here are the year’s top 10 most-read articles, each with a brief description. We’re excited to remain a dependable resource for the ALS community in…

Five toxic chemicals in air may raise, by 3 to 6 times, risk of ALS

Exposure to certain toxic airborne chemicals used in industry significantly increases — by up to six times — the odds of developing amyotrophic lateral sclerosis (ALS), a study suggests. Findings underscore the importance of surveillance programs testing exposure to these airborne pollutants, especially among populations at risk. The study,…

LifeArc grant to fund research into repurposing therapies for MND

LifeArc, a U.K.-based independent medical research charity, is offering £5 million (about $6 million) to scientists around the world as part of a grant program to tackle motor neuron disease (MND) using repurposed or combined medicines. The program is part of the Motor Neuron Disease Translational Challenge, which…

PrimeC can significantly slow ALS progression, PARADIGM trial finds

People with amyotrophic lateral sclerosis (ALS) given PrimeC in the PARADIGM Phase 2b trial — and who did not diverge in major ways from the trial’s rules — experienced a significant slowing in disease progression compared with a placebo, the treatment’s developer, NeuroSense Therapeutics, announced. This finding…

Relyvrio reduces inflammatory biomarkers in ALS: CENTAUR data

Treatment with Relyvrio (sodium phenylbutyrate and taurursodiol) significantly reduced blood levels of neuroinflammatory biomarkers in people with amyotrophic lateral sclerosis (ALS) as early as three months, according to a post hoc analysis of the CENTAUR trial. Data from the Phase 2 study (NCT03127514) demonstrated that reductions in…